Bellevue Group AG Sells 15,463 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Bellevue Group AG decreased its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 6.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 223,816 shares of the company’s stock after selling 15,463 shares during the quarter. Bellevue Group AG owned approximately 0.49% of Omnicell worth $8,422,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Covestor Ltd lifted its holdings in Omnicell by 65.6% in the third quarter. Covestor Ltd now owns 1,355 shares of the company’s stock valued at $61,000 after buying an additional 537 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Omnicell during the 3rd quarter valued at $62,000. Neo Ivy Capital Management acquired a new position in shares of Omnicell in the 3rd quarter valued at $78,000. Strs Ohio boosted its position in shares of Omnicell by 28.2% in the 4th quarter. Strs Ohio now owns 5,000 shares of the company’s stock worth $188,000 after purchasing an additional 1,100 shares during the last quarter. Finally, Hsbc Holdings PLC acquired a new stake in shares of Omnicell during the third quarter worth $200,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Price Performance

Shares of OMCL stock opened at $29.27 on Tuesday. The company has a quick ratio of 2.13, a current ratio of 2.38 and a debt-to-equity ratio of 0.48. Omnicell, Inc. has a 12-month low of $25.69 and a 12-month high of $75.07. The firm has a fifty day moving average of $29.41 and a 200-day moving average of $31.17. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of -63.63, a price-to-earnings-growth ratio of 105.39 and a beta of 0.84.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, May 2nd. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.17. The firm had revenue of $246.15 million during the quarter, compared to analysts’ expectations of $235.70 million. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. On average, equities research analysts forecast that Omnicell, Inc. will post 0.2 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Benchmark reissued a “buy” rating and issued a $38.00 target price on shares of Omnicell in a research note on Tuesday, April 30th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $42.20.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.